Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) just unveiled an announcement.
IRLAB Therapeutics AB reported significant progress in the first quarter of 2025, with positive regulatory feedback from the EMA aligning with the FDA on Phase III for Mesdopetam and promising Phase I results for IRL757. The company also announced a fully funded IRL757 study in Parkinson’s disease and a Phase IIB study with Pirepemat showing a meaningful reduction in fall frequency, strengthening its market position and operational outlook.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a biopharmaceutical company focused on developing treatments for neurological disorders, particularly Parkinson’s disease. The company engages in research and development of candidate drugs, working closely with regulatory bodies and strategic partners to advance its clinical programs.
Average Trading Volume: 86,754
Current Market Cap: SEK357.4M
For an in-depth examination of IRLAB.A stock, go to TipRanks’ Stock Analysis page.